New vaccine targets Hard-to-Treat EBV cancers
Disease control
Not yet recruiting
This early-stage trial tests a new vaccine called KSD-101 in 55 people with relapsed or refractory EBV-associated blood cancers. The vaccine is designed to train the immune system to attack cancer cells infected with the Epstein-Barr virus. The main goals are to check safety and …
Phase: PHASE1 • Sponsor: Kousai Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC